Puma Biotechnology | PBYI - Ordinary Share Capital


Puma Biotechnology reported $5K in Ordinary Share Capital for its fiscal quarter ending in June of 2024.





Ordinary Share Capital Change Date
Agios Pharmaceuticals USD 59.34M 892K Mar/2026
Alnylam Pharmaceuticals USD 133.73M 290K Jun/2026
Amgen USD 541M 1000K Jun/2026
Biogen USD 146.7M 200K Sep/2025
BioMarin Pharmaceutical USD 193.54M 267K Jun/2026
Daiichi Sankyo JPY 1.82B 30.68M Jun/2026
Exelixis USD 248.88M 4.82M Jun/2026
Gilead Sciences USD 1.24B 1000K Jun/2026
Glaxosmithkline GBP 4.05B 20.6M Mar/2026
Incyte USD 200.98M 1.03M Jun/2026
MacroGenics USD 63.56M 241K Mar/2026
Moderna USD 391M 2M Sep/2025
Novartis USD 1.9B 7.38M Jun/2026
Pfizer USD 5.7B 0 Jun/2026
PTC Therapeutics USD 82.88M 1.41M Mar/2026
Puma Biotechnology USD 5K 0 Jun/2024
Regeneron Pharmaceuticals USD 105M 300K Mar/2026
Roche Holding CHF 796.77M 1.15M Jun/2026
Sarepta Therapeutics USD 105.62M 53K Jun/2026
Takeda JPY 1.58B 460K Jun/2026
TG Therapeutics USD 153.08M 2.23M Jun/2026
Ultragenyx Pharmaceutical USD 98.3M 1.7M Mar/2026
Vanda Pharmaceuticals USD 58K 0 Dec/2024
Vertex Pharmaceuticals USD 253.3M 900K Jun/2026